Opko Health (OPK) reported quarterly earnings results on Monday, Aug-8-2016. The company said it had a profit of $0.02 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.05. Analysts had a consensus of $-0.03. The company posted revenue of $357.10 million in the period, compared to analysts expectations of $324.11 million. The company’s revenue was up 742.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.09 EPS.
Many Wall Street Analysts have commented on Opko Health. Company shares were Reiterated by Standpoint Research on Jun 21, 2016 to “Buy”, Firm has raised the Price Target to $ 18 from a previous price target of $16 .Standpoint Research Initiated Opko Health on Jun 3, 2016 to “Buy”, Price Target of the shares are set at $16.
Opko Health opened for trading at $10 and hit $10.12 on the upside on Friday, eventually ending the session at $10.11, with a gain of 1.40% or 0.14 points. The heightened volatility saw the trading volume jump to 34,15,471 shares. Company has a market cap of $5,535 M.
In a different news, on Aug 3, 2016, Gamma Investments Trust Frost (CEO) purchased 10,000 shares at $9.88 per share price. According to the SEC, on May 17, 2016, Robert A Baron (director) sold 37,500 shares at $9.83 per share price. On Mar 18, 2016, Jane Ph D Hsiao (Vice Chairman & CTO) purchased 1,200 shares at $10.65 per share price, according to the Form-4 filing with the securities and exchange commission.
OPKO Health Inc. (OPKO) is a biopharmaceutical and diagnostics company. The Company is involved in developing a range of solutions to diagnose treat and prevent various conditions including point-of-care tests laboratory developed tests (LDTs) molecular diagnostics tests and pharmaceuticals and vaccines. It operates in two segments: pharmaceutical and diagnostics. Its pharmaceutical segment consists of two operating segments pharmaceutical research and development segment and pharmaceutical operations. Its diagnostics segment consists of pathology operations and point-of-care and molecular diagnostics operations. It owns pharmaceutical operations in Chile Spain Mexico Israel Uruguay and Brazil. The product pipeline includes several pharmaceutical compounds and technologies in research and development for a range of indications and conditions.